News | May 07, 2021
Lonza announces expansion plans for mammalian manufacturing facilities
The facility is expected to be completed in 2024
The facility is expected to be completed in 2024
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
Apart from the above, it was also decided that Basic Customs Duty on import of COVID-19 vaccines be also exempted with immediate effect for a period of 3 months
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
The production capacity is now ramped up to 90 lakh vials per month whereas earlier it was 40 lakh vials/month
Port chairpersons have been asked to personally supervise logistic operations to ensure unhindered movement of such consignments for berthing of such vessel on top priority in the port
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
Subscribe To Our Newsletter & Stay Updated
